Compare GSK plc (GSK) vs Invesco S&P 500 Momentum ETF (SPMO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Invesco S&P 500 Momentum ETF — how do they compare? GSK plc trades at $52.71 (market cap $101.34B), while Invesco S&P 500 Momentum ETF trades at $144.66. The key difference: GSK plc pays a 3.49% dividend while Invesco S&P 500 Momentum ETF pays none. Which is the better fit depends on your goals.
| GSK | SPMO | |
|---|---|---|
Market Cap | $101.34B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $61.18 | $161.66 |
52-Week Low | $36.20 | $107.84 |
Enterprise Value | $121.95B | — |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
SPMO trades at $145.12, down 5.06% today amid neutral technical signals. The ETF maintains bullish moving averages but faces resistance near $150. Recent news highlights strong momentum performance with 7.5% gains in June 2026 (ETF Trends, 2026-07-01), though concentrated tech exposure introduces volatility. A $0.25 dividend is scheduled for June 2026.
Outlook remains constructive given AI-driven momentum tailwinds, but high concentration in tech sectors poses risks during market rotations. Analyst sentiment is mixed with neutral ratings outweighing buys. Key support sits at $143, with upside potential if momentum resumes above $152 resistance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Invesco S&P 500 Momentum ETF
SPMO is designed to track the investment results of the S&P 500 Momentum Index. This index measures the performance of stocks in the S&P 500 that exhibit the highest momentum, or the greatest price appreciation, over the trailing 12 months, while excluding the most recent month. By investing in these high-momentum stocks, SPMO seeks to capitalize on the historical trend that stocks with strong recent performance tend to continue that performance in the near term, offering a systematic approach to factor investing within the large-cap U.S. equity market.
Read more on SPMO →
